Astrazeneca Pharma India Ltd vs Kabra Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8501 as of 18 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Kabra Drugs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Kabra Drugs Ltd changed from ₹ 2 crore on March 2022 to ₹ 26.27 crore on March 2025 . This represents a CAGR of 90.37% over 4 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Kabra Drugs Ltd for the Dec '25 is ₹ 30.6 crore as compare to the Sep '25 revenue of ₹ 19.94 crore. This represent the growth of 53.46% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Kabra Drugs Ltd for the Dec '25 is ₹ 2.62 crore as compare to the Sep '25 ebitda of ₹ 2.22 crore. This represent the growth of 18.02% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Kabra Drugs Ltd changed from ₹ -0.55 crore to ₹ 2.57 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Kabra Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Kabra Drugs Ltd

Kabra Drugs Limited was incorporated as a Limited Company on August 22, 1989.
The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical.
The commercial production commenced in 1991.
Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.
The Company has 500+ products across India. The Company was incorporated with a mission to enrich the lives through pharmaceutical solutions which are innovative, high-quality and accessible to every family it serves.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Kabra Drugs Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Kabra Drugs Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,254 Cr while Market cap of Kabra Drugs Ltd is 56 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Kabra Drugs Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Kabra Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Kabra Drugs Ltd?

As of May 18, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8501.8. On the other hand, Kabra Drugs Ltd stock price is INR ₹23.85.

How do dividend payouts of Astrazeneca Pharma India Ltd and Kabra Drugs Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Kabra Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.